2023 World Conference on Lung Cancer (Posters)-EP12.01. L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI

EP12.01. L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the risk of developing brain metastases in patients with non-small cell lung cancer (NSCLC) based on the type of EGFR mutations, specifically exon 19 deletion or L858R. The study found that patients with the L858R mutation had a significantly lower median intracranial progression-free survival (icPFS) compared to patients with exon 19 deletion. In patients without brain metastases, those with exon 19 deletions had no reported progression-free survival, while those with the L858R mutation had a median icPFS of 59.1 months. Additionally, in patients without brain metastases, the L858R mutation was associated with a higher rate of developing new CNS lesions compared to patients with exon 19 deletion. <br /><br />The study suggests that the L858R mutation is associated with a higher risk of brain metastasis development and a lower intracranial progression-free survival. This highlights the need for therapies with higher intracranial activity in this subgroup of patients. The study was conducted at a Mexican institution and included 324 patients with advanced NSCLC and EGFR del exon 19 and L858R common mutations, who were treated with upfront EGFR TKI (first, second, and third generation). <br /><br />In conclusion, this study provides valuable insights into the risk of brain metastases in patients with NSCLC based on specific EGFR mutations. The findings suggest that the L858R mutation is associated with a higher risk and worse outcomes regarding brain metastases compared to exon 19 deletion. Further research and development of targeted therapies with higher intracranial activity may be needed to improve outcomes in this subgroup of patients.

Asset Subtitle

Oscar Arrieta

Meta Tag

Speaker Oscar Arrieta

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

brain metastases

non-small cell lung cancer

NSCLC

EGFR mutations

exon 19 deletion

L858R mutation

intracranial progression-free survival

icPFS

CNS lesions

EGFR TKI